General Information of DTT (ID: TTRK9JT)

DTT Name Neuropeptide Y receptor type 1 (NPY1R) DTT Info
Gene Name NPY1R

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
NEUROPEPTIDE-Y DMINQP1 N. A. N. A. Phase 2 [1]
------------------------------------------------------------------------------------
3 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
H-409/22 DMYJ9CF Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [2]
BIBP 3226 DMYBR9D Hypertension BA00-BA04 Terminated [4]
SR 120819A DMETDFM Eating disorder 6B82 Terminated [5]
------------------------------------------------------------------------------------
2 Preclinical Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
GI-264879A DM25N8B Obesity 5B81 Preclinical [3]
PD-160170 DMB9Z4C Heart disease BA41-BA42 Preclinical [3]
------------------------------------------------------------------------------------
20 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [6]
AcPYY(22-36) DMDEFPS Discovery agent N.A. Investigative [7]
Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMVWM75 Discovery agent N.A. Investigative [8]
BIBO3304 DML7HFP Discovery agent N.A. Investigative [9]
BMS-189323 DM7GUDC Discovery agent N.A. Investigative [10]
BMS-193885 DM1ZBU3 Discovery agent N.A. Investigative [11]
BMS-245782 DM5SNMQ Discovery agent N.A. Investigative [10]
H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 Discovery agent N.A. Investigative [8]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [8]
J-104870 DMCS4BL Discovery agent N.A. Investigative [12]
LRHYLNLLTRQRY-NH2 DMY1807 Discovery agent N.A. Investigative [13]
NPY-1 antagonist DM1MOG8 Eating disorder 6B82 Investigative [14]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [8]
PYY(22-36) DM725FL Discovery agent N.A. Investigative [7]
S-19528 DM589XM Eating disorder 6B82 Investigative [14]
S-25585 DMBUD1M Eating disorder 6B82 Investigative [14]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [8]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV Discovery agent N.A. Investigative [8]
[125I]GR231118 DMFWE4H Discovery agent N.A. Investigative [15]
[Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMWFGBC Discovery agent N.A. Investigative [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Investigative Drug(s)
Molecule Interaction Atlas

References

1 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
2 In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
5 SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
6 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
7 Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41.
8 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.
9 Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul Pept. 2005 Jul 15;129(1-3):73-8.
10 Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8.
11 Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg Med Chem Lett. 2002 Feb 11;12(3):379-82.
12 The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91.
13 A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9.
14 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
15 [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46.